RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Does TH already know the drug works?Let's remember that TH1902 was never intended to be a cure to cancer. So yes, resistant cancer cells will survive especially in advanced cancers with a lot a genetic heterogeneity. If the proof of concept is established with TH19P01/sortilin ligand/receptor combo through the clinical trial on TH1902, that will be the key, because if the proof of concept is established, then TH1902 or the docetaxel part will be just one possibility. In TH1902, if the concept of concentrating docetaxel in sortilin overexpressing cancer cells works, the efficacy in the end will depend on the efficacy of high intracellular doses of docetaxel. But if, for some reasons, docetaxel is not efficacious on certain cancer cells, if the combo TH19P01/sortilin works, it will not be the end of the story, in fact, just the begining. That's why in this trial, the key is the proof of concept. After that, TH19P01 could be coupled with many other cytotoxic agents, some more potent than docetaxel or efficacious on docetaxel resistant cells.